253 related articles for article (PubMed ID: 12621386)
1. Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo.
Lowry JA; Kearns GL; Abdel-Rahman SM; Nafziger AN; Khan IS; Kashuba AD; Schuetz EG; Bertino JS; van den Anker JN; Leeder JS
Clin Pharmacol Ther; 2003 Mar; 73(3):209-22. PubMed ID: 12621386
[TBL] [Abstract][Full Text] [Related]
2. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN;
Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518
[TBL] [Abstract][Full Text] [Related]
3. Red wine-cisapride interaction: comparison with grapefruit juice.
Offman EM; Freeman DJ; Dresser GK; Munoz C; Bend JR; Bailey DG
Clin Pharmacol Ther; 2001 Jul; 70(1):17-23. PubMed ID: 11452240
[TBL] [Abstract][Full Text] [Related]
4. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms.
Pearce RE; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 2001 Dec; 29(12):1548-54. PubMed ID: 11717173
[TBL] [Abstract][Full Text] [Related]
6. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin.
Huwyler J; Wright MB; Gutmann H; Drewe J
Curr Drug Metab; 2006 Feb; 7(2):119-26. PubMed ID: 16472102
[TBL] [Abstract][Full Text] [Related]
7. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.
Kirby B; Kharasch ED; Thummel KT; Narang VS; Hoffer CJ; Unadkat JD
J Clin Pharmacol; 2006 Nov; 46(11):1313-9. PubMed ID: 17050796
[TBL] [Abstract][Full Text] [Related]
9. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
10. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between in vitro inhibition of CYP3A-mediated metabolism by a PPAR-gamma agonist and its effect on the clinical pharmacokinetics of midazolam, an in vivo probe of CYP3A activity.
Fayer JL; Zannikos PN; Stevens JC; Luo Y; Sidhu R; Kirkesseli S
J Clin Pharmacol; 2001 Mar; 41(3):305-16. PubMed ID: 11269571
[TBL] [Abstract][Full Text] [Related]
12. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
13. Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe.
Robertson SM; Formentini E; Alfaro RM; Falloon J; Penzak SR
Pharmacotherapy; 2006 Aug; 26(8):1051-9. PubMed ID: 16863481
[TBL] [Abstract][Full Text] [Related]
14. Influence of grapefruit juice on cisapride pharmacokinetics.
Gross AS; Goh YD; Addison RS; Shenfield GM
Clin Pharmacol Ther; 1999 Apr; 65(4):395-401. PubMed ID: 10223776
[TBL] [Abstract][Full Text] [Related]
15. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Ibrahim A; Karim A; Feldman J; Kharasch E
Anesth Analg; 2002 Sep; 95(3):667-73, table of contents. PubMed ID: 12198057
[TBL] [Abstract][Full Text] [Related]
16. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
18. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
19. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
20. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Phimmasone S; Kharasch ED
Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]